Detalles de la búsqueda
1.
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
J Infect Dis;
215(6): 920-927, 2017 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453836
2.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
HIV Clin Trials;
17(1): 29-37, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899540
3.
Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.
J Antimicrob Chemother;
70(9): 2632-8, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26108607
4.
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
HIV Clin Trials;
16(1): 30-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25777187
5.
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Antimicrob Agents Chemother;
58(10): 6145-50, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092710
6.
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
HIV Clin Trials;
15(5): 218-30, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25350960
7.
HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.
Antimicrob Agents Chemother;
58(9): 5640-1, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25125565
8.
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
J Acquir Immune Defic Syndr;
78(2): 209-213, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29481486
9.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
HIV Clin Trials;
18(4): 164-173, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28891788
10.
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
Antivir Ther;
22(6): 495-502, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28091393
11.
Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
J Acquir Immune Defic Syndr;
68(5): 519-26, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25559592
12.
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Antivir Ther;
20(3): 317-27, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25321623
13.
Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
Antiviral Res;
101: 131-5, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24291780
14.
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
J Acquir Immune Defic Syndr;
65(3): 318-26, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24525469
15.
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
J Acquir Immune Defic Syndr;
59(1): 47-54, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21997204
Resultados
1 -
15
de 15
1
Próxima >
>>